Skip to main content
padlock icon - secure page this page is secure

Design, Synthesis and Biological Evaluation of Scutellarein Derivatives as Potential Anti-Alzheimer's Disease Candidates Based on Metabolic Mechanism

Buy Article:

$68.00 + tax (Refund Policy)

In order to improve the metabolic stability and bioavailability of scutellarin, some derivatives of its main metabolite (scutellarein) were designed and synthesized. The antioxidant activities of these target products were assessed by measuring its scavenging capacities toward DPPH and the protective effects on H2O2-induced cytotoxicity in PC12 cells. The results showed that the target compound 7g had a higher antioxidant activity than scutellarin. Thus 7g may be considered as a novel potent anti-Alzheimer's Disease drug candidate.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alzheimer's disease; Alzheimer's disease (AD); Antioxidant; DPPH; Derivative; Metabolism; PC12; Scutellarein; Scutellarin; Synthesize; amyloid β protein; anti-Alzheimer's Disease drug candidate; cytotoxicity; neuroprotection; pathophysiological; peroxynitrate; scutellarein

Document Type: Research Article

Publication date: January 1, 2012

More about this publication?
  • Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more